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One difficulty in studying epithelial tumors has been the inability to isolate pure samples for DNA
and RNA analysis. Prostate cancer, with its infiltrative nature, is particularly challenging. The
Combination of several new technologies should help overcome these hurdles. Laser capture
microdissection uses a laser beam to achieve transfer of pure cell populations for isolation of
DNA, RNA, and protein. High-throughput analysis of these samples can be achieved by using
cDNA expression microarrays. High-density tissue microarrays should allow for validation of
differentially expressed genes. This review will concentrate on the application of laser capture
microdissection, cDNA microarrays, and tissue microarrays in the area of prostate cancer
research. Copyright # 2001 John Wiley & Sons, Ltd.
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Introduction
One difficulty in studying epithelial tumours has been
the inability to isolate pure samples for DNA and
RNA analysis. Prostate cancer (PCA), with its infil-
trative nature, is particularly difficult. In the past, most
molecular studies have concentrated on the analysis
of bulk tissue samples. That is, samples that were
collected without careful pre-dissection of other tissue
elements, including supporting stroma, microvascula-
ture, and inflammatory cells. Several new technologies,
however, allow us to overcome these hurdles and add
in the precise evaluation of near-pure samples of
benign or malignant cell populations.
These technologies include laser capture microdissec-
tion (LCM), which was developed at the National
Cancer Institute at the National Institutes of Health
(Bethesda, MD, USA) and initially described by
Emmert-Buck et al. [1]. LCM allows for the precise
isolation of individual cells of interest using a micro-
scope to guide laser transfer of the desired tissues. Once
the tissues have been successfully transferred, molecular
analysis, including DNA and RNA extraction, is
possible. The second major high-throughput technology
which should offer tremendous insight into the field of
cancer biology and, in particular, PCA research is the
development of cDNA microarrays. These arrays allow
for the simultaneous evaluation of thousands of genes
from different populations. By using cDNA microarray
technology, one can assess the over- and under-
expression of genes in a tumour population compared
with normal populations of cells. The third technology,
which can be used in close association with cDNA
microarrays, is high-density tissue microarrays.
High-density tissue microarrays, as initially described
by Kononen et al. [2], allow for the evaluation of
hundreds of formalin-fixed, paraffin-embedded tissue
samples (e.g. benign, dysplasia, tumour) on a single
standard glass slide. This high-throughput method to
evaluate protein expression is extremely important,
given the large number of candidate genes discovered
through cDNA microarray technology.
This review will concentrate, then, on the application
of LCM, cDNA microarrays, and tissue microarrays in
the area of PCA research.
Laser caption microdissection and its role
in the evaluation of prostate cancer
One of the major goals of the Cancer Genome Anatomy
Project (C-GAP) is the construction of cDNA libraries
from pathological tissue [3]. It was recognized early that
two main sources of tissue were available for creating
cDNA libraries. The first source was bulk tissue cDNA
from RNA derived from large tumours. This strategy
was appropriate for certain tumour types, such as lung,
colon, and ovary, that are most often surgically resected
as mass lesions that are grossly identifiable. However, it
was recognized that regardless of tumour type, bulk
tissue, even in its highest purity, still has potential
contamination from stromal, endothelial, and inflamma-
tory cells. This is a particular problem in the evaluation
of PCA (prostate cancer). The prostate gland is a
complex organ that is composed of epithelial and
stromal cells. The normal epithelial component often
represents only a small percentage (5–10%) of the entire
prostate. PCAs are often seen to grow in an infiltrative
pattern, with individual tumour acini infiltrating through
stroma and directly adjacent to benign prostatic
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epithelium (Figure 1). Therefore, a second approach for
collecting pathological tissues in the C-GAP project was
to use the newly developed LCM technique to develop a
cDNA library [4,5].
LCM was developed by Emmert-Buck et al. at the
National Cancer Institute (NCI) of the National
Institutes of Health (Bethesda, MD, USA) [1]. LCM
was born out of a need to isolate pure populations of
tumour, normal, and dysplastic tissues for the C-GAP
project. The most widely used LCM device is the
apparatus developed by the NCI and commercially
distributed by Arcturus Engineering (Mountain View,
CA, USA). In this version, LCM uses a laser beam and
a special thermoplastic polymer transfer film, which is
bonded to the underside of a transfer cap (see
Figure 2A). The cap is set on the surface of the tissue
and a laser pulse is sent through the transparent cap,
expanding the thermoplastic polymer. The selected
cells adhere to the transfer cap and can be lifted off the
tissue and placed directly into an Eppendorf tube for
extraction (Figure 2B). Precise LCM can achieve
transfer of pure cell populations (Figure 3).
LCM represents a major advance over previous
methods of microdissection, which often used a
30-gauge or smaller needle to dislodge tumour under
direct bright field visualization [6]. LCM has now been
used successfully for numerous studies in the field of
prostate [7–10], breast [11], lymphoma [12–14], and
lung [15,16] cancer research. In the field of PCA
research, the initial studies have used LCM to evaluate
molecular alterations at the DNA level. Lutchman
et al. were interested in analysing dermatin, a cyto-
skeleton protein, which is encoded by a gene on
chromosome 8p21.1 [17]. They employed LCM to
Figure 1. The infiltrative nature of prostate cancer makes the isolation of pure tumour samples difficult. (A) Example of a localized
prostate cancer; (B) tumour cells (red) are seen in close association with benign glands (blue) (A, B) r100
A B
Figure 2. Laser capture microdissection (LCM) uses a laser beam
and a special thermoplastic polymer transfer film, which is bonded
to the underside of a transfer cap (see A). The cap is set on the
surface of the tissue and a laser pulse is sent through the transparent
cap, expanding the thermoplastic polymer. The selected cells are
now adherent to the transfer cap and can be lifted off the tissue and
placed directly onto an Eppendorf tube for extraction (B)
Figure 3. LCM can isolate pure populations of cells. In this example, benign secretory cells are successfully transferred, leaving
behind basal cells (arrows). (A, B) r200
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identify abnormalities at the locus of interest using loss
of heterozygosity analysis from laser capture micro-
dissected samples of prostate tissues. A second study
by Rubin et al. required the use of LCM to study loss
of heterozygosity at 10q23.3, a region that has been
associated with multiple tumours, including glioblas-
toma multiforma, melanoma, endometrial carcinoma,
and PCA [10]. 10q23 was also the site of PTEN/
MMAC1, which has been found to be mutated in
prostate cancer cell lines, xenographs, and hormone
refractory PCA tissue specimens. This study required
using several microsatellite markers in the region of
10q23. The results indicated an increase in genetic
alterations as determined by loss of heterozygosity
analysis in lymph node-positive prostate cancers
(pT2–3, N+), suggesting that 10q23.3 is an important
region in the development of metastatic PCA. What
was critical to the successful completion of this study
was the ability to isolate pure tumour samples from
cases of clinically localized PCA, where often the
tumour was either small in size or extremely infiltrative
in nature. These types of loss of heterozygosity analysis
studies are similar to those that have been done in the
past using microdissection with 30-gauge needles [6].
However, there are two important differences. The first
is that the PCA isolated using LCM is much purer; of
the order of 95–100% pure PCA samples can be
isolated. The second difference is that without LCM,
a significant percentage of PCA samples could not be
used. In the Rubin et al. study, probably 30–40% of the
cases could only be microdissected using LCM [10].
This means that without LCM, a large percentage of
smaller tumours would need to be excluded from the
molecular analysis, tending to bias the study of larger
or bulky tumours.
More recently, LCM has been successfully used to
extract mRNA from frozen tissues [1,5,18–22]. Fend
et al. [23] developed a rapid immunostaining method of
frozen sections to allow for an ultra-specific LCM of
frozen tissues. This technical advance might be useful,
as specific cell subtypes are needed, such as basal cells
in prostate or various subcomponents of an inflamma-
tory infiltrate (e.g. T- or B-cells). This protocol may
also be useful in the identification and isolation of cells
from a similar population, which differ by their
metabolic state. For example, one could do a study
on PCA cells that are proliferative as determined by
Ki-67 (MIB-1) immunostaining. This method may also
be useful in identifying cells that are morphologically
difficult to identify using standard LCM protocols.
The standard protocol requires using an un-
coverslipped frozen section (Arcturus Engineering,
Mountain View, CA, USA). Therefore, the use of a
rapid immunohistochemistry method, which might
take an additional 12–25 minutes, allows for a strong
contrast provided by the DAB (chromogen) staining.
LCM has also been used in a proteomic approach to
identify intracellular protein within PCA and normal
secretory cells [8]. Ornstein et al. used one-dimensional
and two-dimensional polyacrylamide gel electrophor-
esis (PAGE) on cellular lysates from LCM isolated
prostate cells. They found that prostate-specific antigen
(PSA) existed in the free (unbound) form in both PCA
and normal prostate secretory cells. They concluded
that binding of PSA to alpha-1-antichymotrypsin
occurs outside the cell and is not different between
prostate cancer and benign cells. Ornstein et al., in
another proteomic study, used LCM of human
prostate cancer cells to look for quantitative and
qualitative alterations in protein [7]. This particular
approach is required because of previously mentioned
contamination from inflammatory cells, vessels, and
non-malignant epithelial cells. They were able to use
8 mm thick frozen section slides to extract protein,
estimating a transfer (e.g. dissection) of 40–50 000 cells
at a level of 95% or greater purity. The cells were then
lysed and two-dimensional PAGE was performed
overnight. The results were digitally scored, which
allowed for a comparison of protein fingerprints
between PCA and normal cells. Only spots that were
unique to either PCA or normal prostate were
considered altered. In their initial studies, less than
98% of the proteins were determined to be identical in
both benign and malignant populations. However, six
distinct tumour-specific proteins were identified. The
approach is successful in identifying unique sets of
proteins that could potentially be used for clinically
relevant serum tests. Another important finding in this
study was the discrepancy between in vivo PCA and
prostate tumour cell line (i.e. LNCaP and PC-3) protein
expression. They highlight the limited usefulness on data
gathered on serially passaged tumour cell lines.
Other novel approaches using single-cell LCM and
proteomics have identified ways of performing analy-
tical measurements of protein number in laser capture
microdissected cells [9].
LCM has been used successfully to extract DNA,
mRNA, and to perform proteomics. All of these studies
are technically difficult and require the most stringent of
conditions in order to ensure reproducible results.
However, the potential benefit of determining genetic
alterations that are specific to a selected and pure
population of cells is significantly more informative than
molecular analysis performed on bulk tissue samples.
cDNA expression arrays and high-density
tissue microarrays
One of the new emerging technologies in the post-
genomic era are cDNA expression microarrays. These
arrays can carry over 50 000 genes, which can be
analysed in a single experiment. This approach allows
for the evaluation of all potential candidate genes and
pathways that may be related to tumour progression or
metastasis. This approach should allow for rapid
results, which otherwise would have taken years and
exhausted existing tissues banks [24]. Initial expression
array studies in the field of PCA have been performed
on tumour cell lines, primarily due to the difficulty in
isolating pure tumour samples. Vaarala et al. examined
cDNA expression between an androgen-dependent and
an androgen-independent LNCaP prostate tumour cell
82 M. A. Rubin
Copyright # 2001 John Wiley & Sons, Ltd. J Pathol 2001; 195: 80–86.
line [25]. In their experiment, they examined 7075
human cDNAs, which were evaluated for over- and
under-expression. They found that in the hormone-
sensitive LNCaP cell lines several genes, such as
Kallikrein 3 (PSA), Kallikrein 2 (hK2), and androgen
receptor, were overexpressed. Genes were reported as
overexpressed in hormone-insensitive LNCaP cells and
these included TNF receptor-associated factor-binding
protein, TNF receptor-associated factor 3, an EST
similar to galectin-1, and folistatin. The latter two gene
products have previously been associated with hormone
refractory PCA. These results are interesting because
they confirm a discrete set of differentially expressed
genes in two PCA cell lines that differ in their ability to
grow in the absence of androgen. Carlisle et al. used a
similar approach to evaluate a prostate cell line, 8.4,
and a melanoma cell line, UACC903 [26]. This
experiment evaluated 5184 cDNAs, which were spotted
onto a nylon membrane filter. EST sequences derived
from prostate cDNA libraries were used. This work was
part of the C-GAP project. The key findings in this
study were first to evaluate how reproducible results
were from similar cell lines. They demonstrated excel-
lent correlation coefficients when comparing results for
two separate hybridizations of the same cell lines
(R=0.9). When they compared differences between the
prostate and melanoma cell lines, they found that 89%
of the genes showed overexpression for the prostate cell
line 8.4. The melanoma cell line, which one would
anticipate to have far fewer similarities with the original
prostate cDNA libraries, had only 28% of the cDNAs
which were expressed. Overexpression of housekeeping
genes such as keratin in the PCA cell lines, but not the
melanoma cell lines, confirmed the results.
Bubendorf et al. combined cDNA and tissue micro-
array technologies (see below) to examine differences
in gene expression between well-characterized PCA cell
lines [24]. They examined gene profile differences
between hormone-sensitive CWR22 and hormone
refractory CWR22R PCA cell lines. The results were
validated on a tissue microarray of specimens taken
from a broad spectrum of patients with PCA. Two
types of commercially available cDNA arrays were
used for the purpose of this experiment (Clontech
Laboratories, Inc., Palo Alto, CA and Research
Genetics, Inc., Huntsville, AL, USA) with a total of
5184 genes. A discreet set of genes (0.7% or 37 of 5184)
were up-regulated in the hormone-resistant PCA cell
line with more than a two-fold increase and 2.6% (135/
5184) of genes were down-regulated by more than 50%.
Insulin-like growth factor binding protein 2 (IGFPB2)
and the 27 kd heat-shock protein (HSP27) were among
the most consistently overexpressed genes in the
population of hormone refractory cells (CWR22R).
These two cDNA microarray results were confirmed
using immunohistochemistry on high-density tissue
microarrays. IGBBP2 was expressed in 100% of the
hormone refractory PCAs, 36% of the clinically
localized PCA, and 0% of benign prostatic tissue
(two-sided p value=0.0001). For HSP27, overexpres-
sion was seen in 31% of the hormone-resistant PCA
versus 5% of the clinically localized PCA and 0% of
benign prostatic tissue (two-sided p value=0.0001).
Overall, they found 170 genes or 3.3% differentially
expressed (i.e. over- or under-expressed). This level of
molecular complexity will be important to evaluate in
clinical samples. They also noted that it remains
critically important not only to screen for expression
of many different genes, but also to screen many
different tumour tissues and establish an accurate
frequency of involvement of these genes in the different
stages of PCA progression.
Two additional studies are noteworthy in their
ability to link LCM with expression array analysis.
Neither of these studies was performed in prostate;
however, their approaches are important because they
were able to perform cDNA analysis of LCM isolated
breast and neural cells. In the first experiment, Luo
et al. examined gene expression profiles of neural
tissues from LCM isolated samples [27]. RNA ampli-
fication was performed using a linear amplification
with the T7 RNA polymerase. Validation was per-
formed using several more standard methodologies
including quantitative RT-PCR and northern blot
analysis to demonstrate protein expression differences.
They were able to identify different gene expression
profiles for histologically distinct neural populations.
In another study examining breast cancer, Sgroi et al.
compared cDNA expression from LCM breast cancers
[28]. They used a custom-made nylon membrane
cDNA array and examined a total of 8084 genes.
Total RNA was extracted using LCM. They estimated
that a total of 1.7r104 to 2.0r104 cells were used for
RNA extraction. These cells were reverse-transcribed
and labelled with 33P. They divided the RNA into
several pools, which were used to verify overexpressed
genes using RTQ-PCR. Alternatively, protein expres-
sion was also confirmed using immunohistochemistry
in the cases where antibodies were available. In this
study, 90 genes had significantly altered levels of
expression (two-fold or greater). When they compared
gene expression differences from metastatic and inva-
sive cancers with that of normal breast, they found
overexpression of such genes as apolipoprotein-D
(15.2-fold increase), BRACA1 (3.8-fold increase), heat
shock factor protein-1 (6.4-fold increase), and annexin-1
(21.7-fold increase). There were also numerous ESTs
that were overexpressed.
The linking of high-density tissue microarrays with
cDNA microarray technology offers a way to confirm
differentially expressed genes in a large number of
clinical samples without exhausting banked archival
tissue, which is a real concern at academic research
centres. High-density tissue microarrays are the subject
of another review article [29] in this issue of the journal;
therefore this discussion will be limited to the use of
tissue microarrays for the study of PCA. One of the first
studies in PCA using tissue microarrays was performed
by Bubendorf et al. [30]. They examined amplification of
androgen receptor, cyclin D1, and cMyc using fluores-
cence in situ hybridization (FISH) on tissue microarrays.
They found that both Myc and androgen receptor were
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overexpressed in hormone refractory PCA with respect
to clinically localized hormone-sensitive PCA. Some
advantages of their approach included the successful
analysis performed on one slide with 32 samples of BPH,
223 samples of primary PCA, 54 locally recurrent PCAs,
and 62 metastatic PCAs from patients with hormone
refractory PCA. In total, 371 samples were examined
with five different probes.
Bubendorf et al. did not find c-erbB2/Her2neu
amplification in any of the prostate samples examined
[24]. These results were consistent with two previous
studies which used standard slides [31,32]. However,
Ross et al. did find high amplification of c-erbB2/
Her2neu in two published studies [33,34]. The four
previous studies were all performed on standard slides.
Therefore one of the major advantages of the tissue
microarray approach was that using a small amount of
tissue in a single experiment, they were able to identify
the low probability that c-erbB2/Her2neu plays an
important role in the progression of PCA. This initial
study would have made it relatively unnecessary to
repeat them in studies using standard slides.
The small size of the samples used for tissue
microarrays has been discussed in several recent
papers [2,35,36]. Some have criticized the small size of
the tissue samples used for tissue microarrays. The
major concern has to do with the lack of representa-
tion of the original tumour from which the sample
comes. However, it is important to point out that the
question being asked is not what the protein expression
or gene amplification is for an individual patient to
determine treatment, but instead to profile the expres-
sion of a large population of PCA tumours. The result
should indicate whether a specific protein is over-
expressed in the population of interest, such as
hormone refractory PCA. If low expression is observed
in hundreds of samples, there is a very high probability
that this is a good estimate of what one would see
Figure 4. Schematic representation of a high-throughput approach performing precise molecular profiling of prostate cancer. The
prostate gland is immediately retrieved from the operating room. After appropriate prostate tissue is taken for pathological tumour
staging, frozen tissues samples are acquired for research. Laser capture microdissection is performed and total RNA is extracted and
after a linear amplification, is labelled and hybridized on a cDNA microarray. The results are evaluated and important candidate
genes are confirmed using quantitative RT-PCR or high-density tissue microarrays with various stages of prostate tumours
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using standard slides. It is also important to point out
that due to the large number of candidate genes that
need to be examined, the tissue microarray approach
provides an excellent way to conserve tissue. Tissue
microarray technology is a powerful tool for the
molecular profiling of large numbers of tumours
representing the entire disease spectrum of human
prostate cancer progression in vivo [24].
The use of LCM in combination with cDNA
microarrays and confirmation using high-density
tissue microarrays is an intriguing approach
(Figure 4). However, limitations will be in our ability
to analyse these data. The large number of genes that
will be identified as being differentially expressed will
require the development of databases that will allow us
to categorize results. Therefore, not only will we need
to know the specific genes and their function, but we
will also need to be able to group the results in
meaningful pathways that will be helpful in identifying
tumour-specific pathways relevant in the progression
of PCA. Due to the difficulties in analysing gene
expression results, Kaldjian and Giesig (unpublished
study) have employed a system of ‘functional taxon-
omy’ to categorize the data. Selected genes are placed
into 16 different cellular function categories that are
further divided into subcategories. For each sample,
the number of genes in each category can be calculated
and graphed, providing a cellular function fingerprint
of gene expression. This ‘functional taxonomy’
approach will allow us to deal with cDNA expression
array results from numerous experiments from many
patients. By taking this approach, one would hope that
after the analysis of 50–100 tumours, patterns would
develop. As clinical data are linked to these profiles,
outcomes such as PSA biochemical failure, develop-
ment of metastatic disease, or death may demonstrate
unique profiles. Response to treatment may also be
linked to a specific functional profile.
From a practical standpoint, none of the studies
using these new technologies has identified any
clinically significant genes or groups of genes that
have made their way to the bedside. However, we are
at the very early phases of this technology; advances
are anticipated in both the high-throughput analysis
and database development, which should dramatically
increase our likelihood of finding clinically significant
genes or groups of genes that will translate into
diagnostic or therapeutic modalities for men with
PCA.
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